In many cancers, the molecular processes associated with growth and survival are increasingly well characterized, and modern therapies can inhibit intended targets and pathways. Yet even with demonstrable target engagement, durable control in aggressive and advanced disease frequently does not follow. This indicates a limit that is not primarily molecular, but architectural: collapse occurs only when feasibility boundaries are exceeded.
